Evidence map›Paper›PMID 32739643›Full record

ArticlePsychiatry research2020

COMT val158met genotype alters the effects of methamphetamine dependence on dopamine and dopamine-related executive function: preliminary findings.

Rowan Saloner, Mariana Cherner, Erin E Sundermann, Caitlin Wei-Ming Watson, Jennifer E Iudicello, Scott L Letendre, Adarsh Kumar, Ronald J Ellis

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatry research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rowan SalonerSan Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA; Department of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA. Electronic address: rsaloner@ucsd.edu.
Mariana ChernerDepartment of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA.
Erin E SundermannDepartment of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA.
Caitlin Wei-Ming WatsonSan Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA; Department of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA.
Jennifer E IudicelloDepartment of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA.
Scott L LetendreDepartment of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA.
Adarsh KumarDepartment of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, USA.
Ronald J EllisDepartment of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA, USA; Department of Neurosciences, University of California, San Diego, San Diego, CA, USA.
University of California, San Diego · USUniversity of Miami · US

Funding

STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jessica Lynette Montoya · 2001 to 2026
$50.4M
Translational Methamphetamine AIDS Research Center (TMARC)P50DA026306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GRANT, IGOR · 2009 to 2018
$33.9M
Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN)T32DA031098 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello, DAVID J MOORE · 2011 to 2026
$4.6M
Identification of Biomarkers of CNS injury and resilience related to HIV-1 and MethamphetamineR01DA047879 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IUDICELLO, JENNIFER E, LETENDRE, SCOTT L · 2018 to 2022
$3.7M
Mentoring Clinical Researchers at the Intersection of NeuroHIV and Substance AbuseK24DA040550 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERNER, MARIANA · 2015 to 2025
$1.8M
COMT Genotype and Risky Decision Making in HIV and Methamphetamine DependenceR01DA026334 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHERNER, MARIANA · 2009 to 2010
$1.1M
Biomarkers of Blood Brain Barrier Injury in Methamphetamine Use and HIV DiseaseK23DA037793 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IUDICELLO, JENNIFER E · 2014 to 2018
$915k
SuperAging in HIV-infected Adults: Biopsychosocial Predictors of Neurocognitive Aging TrajectoriesF31AG064989 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SALONER, ROWAN · 2019 to 2021
$118k
NIA NIH HHS F31 AG064989NIDA NIH HHS K23 DA037793NIDA NIH HHS K24 DA040550NIDA NIH HHS P50 DA026306NIDA NIH HHS R01 DA026334NIDA NIH HHS R01 DA047879NIDA NIH HHS T32 DA031098NIMH NIH HHS P30 MH062512
6 · The paper itself

Abstract

The Met-allele of the COMT Val158Met polymorphism slows metabolism and increases bioavailability of dopamine (DA) in the prefrontal cortex compared to the Val-allele. Healthy Met-carriers outperform Val-carriers on executive function (EF) tests, yet this 'advantage' disappears in methamphetamine (METH) dependence. Met-carriers may be disproportionately vulnerable to METH-related perturbations of DA, yet it is unknown whether COMT modulates METH effects on CSF DA biomarkers. Participants were 75 METH+ and 47 METH- men who underwent neurocognitive testing, COMT genotyping, and lumbar puncture. CSF was assayed for DA and its metabolite, homovanillic acid (HVA). Separate linear models regressed DA, HVA, and HVA/DA ratios on COMT, METH and their interaction. Pearson correlations examined associations between DA and EF. Significant interactions indicated that METH+ had lower DA and higher HVA/DA ratios among Met/Met, but not Val/Met-or Val/Val. Met/Met-exhibited the highest DA levels among METH-, whereas DA levels were comparable between Met/Met-and Val-carriers among METH+. Higher DA correlated with better EF in METH- Met/Met, but did not predict EF in the entire sample. DA was expectedly higher in METH- Met/Met, yet a discordant genotype-phenotype profile emerged in METH+ Met/Met, consistent with the notion that slow DA clearance exacerbates METH-associated DA dysregulation.

Indexed as

GenotypeAdultAmphetamine-Related DisordersCatechol O-MethyltransferaseDopamineExecutive FunctionHumansMaleMethamphetamineMethionineMiddle AgedPolymorphism, GeneticPrefrontal CortexValineYoung AdultCatechol O-MethyltransferaseCOMT protein, humanDopamineMethamphetamineMethionineValineCatechol-o-methyltransferaseDopamineExecutive functionHomovanillic acidMethamphetaminePrefrontal cortex

Identifiers

PMID32739643
PMCPMC7530039
OpenAlexW3038937712

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.